Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).
about
The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemiaThe trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialCutaneous primary B-cell lymphomas: from diagnosis to treatmentClinical development methodology for infusion-related reactions with monoclonal antibodiesMonoclonal antibody therapy and renal transplantation: focus on adverse effectsInfliximab-Related Infusion Reactions: Systematic ReviewToxicity and management in CAR T-cell therapyGlypican-3 Targeting Immunotoxins for the Treatment of Liver CancerReceptors and transmission in the brain-gut axis: potential for novel therapies. V. Fast and slow extrinsic modulation of dorsal vagal complex circuitsCholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to Fab 2 fragmentsNosocomial Co-Transmission of Avian Influenza A(H7N9) and A(H1N1)pdm09 Viruses between 2 Patients with Hematologic Disorders.Successful long-term monotherapy with rituximab in a patient with chronic lymphocytic leukemia of the B-cell-lineage: a case report.Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignanciesThe clinical development of obinutuzumab for the treatment of follicular lymphoma.Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.Current concepts in the diagnosis and management of cytokine release syndrome.After TGN1412: recent developments in cytokine release assays.Induction of interleukin-6 production by rituximab in human B cells.The spectrum of use of rituximab in chronic lymphocytic leukemiaRole of rituximab in first-line treatment of chronic lymphocytic leukemia.Antibody therapy for chronic lymphocytic leukemia.Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab).Chronic lymphocytic leukemia: treatment options for patients with refractory disease.Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis.Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL).Rapid-infusion rituximab in lymphoma treatment: 2-year experience in a single institution.Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP.Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.Disappointing biotech.Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells.The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapyCytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine stormClinical review: Serious adverse events associated with the use of rituximab - a critical care perspective.Rituximab-Induced Splenic Rupture and Cytokine Release.Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphomaSeverity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?Rituximab-related reversible hepatocellular damage.
P2860
Q24617708-06333343-A351-4E34-9FF1-A17CAB4719EFQ24629295-CEB12027-99AF-4464-A623-21DAAFDB5F99Q26777479-8B6058AD-F858-4C79-9A0F-7DEF5D9055B3Q26798184-E96A9F08-2F1D-4C6E-A0ED-080FC459AB36Q26826880-60D3D18B-6D8E-4E2D-8697-41EA12AD3DF5Q27013835-6D834386-4123-49D0-BE7C-3690042FCE4BQ28075314-0D5447CE-AB14-4FE4-BA94-9A9526B9B281Q28077270-C6852F42-A78A-4229-8603-2EA254D4319DQ28346581-34206736-9771-4595-A2FC-B006A75475FCQ28535018-8F930306-02D7-4BFF-915D-346522E15BE5Q30385714-A5CD1873-7D02-44A6-A07C-013E3D36E9AFQ33380747-4ACF55EB-E627-434A-9971-AB532115EDE5Q33422543-5AF45C37-6EFB-405F-96FC-E4AF4D719FF7Q33565265-316FC2BC-2FC4-4F65-B03F-E97C6DF318B3Q33851168-615FC504-D5C5-4B6B-8C3A-2BE6B5FD783FQ33886879-8211017D-6500-45C8-A7A6-9010D5B1503EQ34299057-2D84E399-C659-49FA-B9D0-799716B97DA8Q34415869-AEAC39C8-338B-4DCE-BD69-EF1A167871C7Q34510030-AD79EC73-486B-463A-86AF-9CDA0A173D79Q34574147-747BB939-EE10-42F5-9AD9-05F300FE2526Q34589909-63B00AC5-A82F-4A24-9CC6-826F581F30CBQ35057971-BC9D1529-F3EC-40F3-BA36-CB849AAD8E77Q35382716-E50AFB23-6F09-416E-A79C-BBD0AB0A5061Q35437978-A7291104-0524-42E4-9F4F-237768289056Q35556806-B9956A0D-3159-47A6-997A-48A0D0F3E37EQ35683808-2D219D80-0DFA-40D0-9990-2ED16743B9DFQ36095143-F54832E7-ABF3-4CB2-8C11-A52769D7A680Q36224763-2FA05873-6C38-4035-986A-8FC166977188Q36228329-A0535CDA-8E9B-482A-A769-E5A96AF3205BQ36285629-18056772-8AA7-4B36-AE8D-92CD35058C86Q36370860-14DEFC67-F339-487C-A9BA-23B356BB0420Q36402637-DF304779-248F-4A33-B557-BE616179199EQ36621100-FEEDC32E-EDF3-449D-8DD3-F5923827FCFFQ36633769-FD2454EF-BF79-42C3-AC4C-4391175934DCQ36688086-54317295-0847-401E-8F1B-6EB5595569E7Q36754719-20F62877-1892-474C-A19B-B10121DBEBD8Q36801911-5344C290-3CF2-4EE0-8179-4D2375614C70Q37064758-83225EB6-FDEF-4C3A-850A-5738C3E0018EQ37114367-625163F6-25D3-4723-A8CA-A2C07E70E5D6Q37193837-623B40F2-E73A-4828-A4DA-C667AC53BA02
P2860
Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Cytokine-release syndrome in p ...... tibody (rituximab, IDEC-C2B8).
@en
type
label
Cytokine-release syndrome in p ...... tibody (rituximab, IDEC-C2B8).
@en
prefLabel
Cytokine-release syndrome in p ...... tibody (rituximab, IDEC-C2B8).
@en
P2093
P921
P1433
P1476
Cytokine-release syndrome in p ...... tibody (rituximab, IDEC-C2B8).
@en
P2093
P304
P407
P577
1999-10-01T00:00:00Z